BillionToOne, Inc. (Ticker: BLLN US) is a United States diagnostics company focusing on prenatal screening and oncology liquid biopsy enabled by its molecular counter platform. BillionToOne plans to list on the Nasdaq Global Select Market on November 6, 2025, following expected pricing on November 5. The IPO comprises 3.85m primary Class A shares at a price range of $49–$55, for expected gross proceeds of around $200m. The company is seeking a market capitalization between $2.5bn and $2.8bn. The deal includes a 5% directed share program. J.P. Morgan is left lead, with Piper Sandler, Jefferies, William Blair, BTIG, Stifel, and Wells Fargo also on the ticket. BillionToOne is proceeding during the government shutdown by removing the delaying amendment, allowing automatic effectiveness 20 days after filing. The company’s tests serve U.S. customers across prenatal and oncology indications.